CERO Stock Overview
An immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CERo Therapeutics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.15 |
| 52 Week High | US$12.80 |
| 52 Week Low | US$0.064 |
| Beta | -0.46 |
| 11 Month Change | 90.91% |
| 3 Month Change | 10.03% |
| 1 Year Change | -98.65% |
| 33 Year Change | -98.52% |
| 5 Year Change | n/a |
| Change since IPO | -98.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| CERO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -43.0% | 4.0% | 2.0% |
| 1Y | -98.6% | 18.0% | 32.4% |
Return vs Industry: CERO underperformed the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: CERO underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| CERO volatility | |
|---|---|
| CERO Average Weekly Movement | 56.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CERO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CERO's weekly volatility has increased from 38% to 57% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 9 | Chris Ehrlich | www.cero.bio |
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.
CERo Therapeutics Holdings, Inc. Fundamentals Summary
| CERO fundamental statistics | |
|---|---|
| Market cap | US$26.08m |
| Earnings (TTM) | -US$5.49m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.0x
P/E RatioIs CERO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CERO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$5.49m |
| Earnings | -US$5.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.037 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -2.8% |
How did CERO perform over the long term?
See historical performance and comparison